FUBIMINA
From Wikipedia, the free encyclopedia
 |
This article may be too technical for most readers to understand. (June 2015) |
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| ChemSpider | 30646758 |
| Chemical data | |
| Formula | C23H21FN2O |
| Molar mass | 360.4 g/mol |
|
|
|
FUBIMINA (also known as BIM-2201, BZ-2201 and FTHJ) is a synthetic cannabinoid that is the benzimidazole analog of AM-2201[1] and has been used as an active ingredient in synthetic cannabis products. It was first identified in Japan in 2013, alongside MEPIRAPIM.[2]
FUBIMINA acts as a reasonably potent agonist for the CB2 receptor (Ki = 23.45 nM), with 12x selectivity over CB1 (Ki = 296.1 nM), and does not fully substitute for Δ9-THC in rat discrimination studies.[3]
Related benzimidazole derivatives have been reported to be highly selective agonists for the CB2 receptor.[4]
See also[edit]
- AM-694
- AM-1235
- AM-2232
- AM-2233
- BIM-018
- JWH-018
- List of AM cannabinoids
- List of JWH cannabinoids
- THJ-2201
References[edit]
- ^ "FUBIMINA". Cayman Chemical. Retrieved 22 June 2015.
- ^ Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014). "Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products". Forensic Toxicology 32 (1): 105–115. doi:10.1007/s11419-013-0217-2.
- ^ Jenny L Wiley, Julie A Marusich, Timothy W Lefever, Kateland R Antonazzo, Michael T Wallgren, Ricardo A Cortes, Purvi R Patel, Megan Grabenauer, Katherine N Moore, and Brian F Thomas (June 2015). "AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice". Journal of Pharmacology and Experimental Therapeutics 354: 328–39. doi:10.1124/jpet.115.225326. PMC 4538877. PMID 26105953.
- ^ Daniel Pagé, Elise Balaux, Luc Boisvert, Ziping Liu, Claire Milburn, Maxime Tremblay, Zhongyong Wei, Simon Woo, Xuehong Luo, Yun-Xing Cheng, Hua Yang, Sanjay Srivastava, Fei Zhou, William Brown, Miroslaw Tomaszewski, Christopher Walpole, Leila Hodzic, Stéphane St-Onge, Claude Godbout, Dominic Salois, Keymal Payza (July 2008). "Novel benzimidazole derivatives as selective CB2 agonists". Bioorganic & Medicinal Chemistry Letters 18 (13): 3695–3700. doi:10.1016/j.bmcl.2008.05.073. PMID 18522867.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
